Companies leading trial announce Kevzara failed to meet primary and secondary endpoints in critically ill COVID-19 patients, so the trial has been halted.
List view / Grid view
Filter the results
The FDA has granted priority review of the Biologics License Application for sutimlimab to treat haemolysis in patients with cold agglutinin disease (CAD).
Heidi West discusses how academia, government and the pharmaceutical industry can work together to potentially repurpose drugs for the treatment of COVID-19.
Sanofi will provide its S protein antigen and GSK will contribute its adjuvant technology in a partnership to develop a COVID-19 vaccine.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
A Phase II/III trial to study Kevzara (sarilumab) as a method to reduce the inflammatory response in the lungs of COVID-19 patients has begun outside of the US.
Led by Sanofi and Regeneron, clinical trials to examine Kevzara (sarilumab) as an effective COVID-19 treatment will begin in the US.
According to its developers, SAR442168 significantly reduced the appearance of new gadolinium (Gd)-enhancing T1-hyperintense brain lesions in the 120 trial patients.
Research has found that the top five pharmaceutical companies averaged a Market Capitalisation decline of five percent in Q3 of 2019.
Sanofi has announced it is to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 billion.
The pharmaceutical company Sanofi is voluntarily recalling its OTC Zantac products in the US and Canada due possible contamination with NDMA.
Why has the pharma industry and its talents lost interest in developing new antibiotics?
A US district court has invalidated Amgen's patent claims for antibodies targeting PCSK9.
Sanofi has won the latest appeal for the patent of its top oncology product, Jevtana (cabazitaxel).
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.